Article and Video CATEGORIES

Cancer Journey

Search By

Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLC
Author
GRACE Videos and Articles

LCAM 2015

 

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

[powerpress]

Get more information about the IMpower-110 Trial and CheckMate-227 Trial.

[ratingwidget post_id=0]

Check out more LCAM videos & posts here.

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora